CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...